Cargando…

Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells

Endoglin (Eng) is a co-receptor of the transforming growth factor β superfamily playing an important role in endothelial dysfunction. TRC105 (carotuximab) is a monoclonal antibody that blocks Eng and its downstream Smad signaling pathway. Here we have investigated for the first time the effects of T...

Descripción completa

Detalles Bibliográficos
Autores principales: Tripska, Katarina, Igreja Sá, Ivone Cristina, Vasinova, Martina, Vicen, Matej, Havelek, Radim, Eissazadeh, Samira, Svobodova, Zuzana, Vitverova, Barbora, Theuer, Charles, Bernabeu, Carmelo, Nachtigal, Petr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490272/
https://www.ncbi.nlm.nih.gov/pubmed/36160139
http://dx.doi.org/10.3389/fmed.2022.845918
_version_ 1784793051483340800
author Tripska, Katarina
Igreja Sá, Ivone Cristina
Vasinova, Martina
Vicen, Matej
Havelek, Radim
Eissazadeh, Samira
Svobodova, Zuzana
Vitverova, Barbora
Theuer, Charles
Bernabeu, Carmelo
Nachtigal, Petr
author_facet Tripska, Katarina
Igreja Sá, Ivone Cristina
Vasinova, Martina
Vicen, Matej
Havelek, Radim
Eissazadeh, Samira
Svobodova, Zuzana
Vitverova, Barbora
Theuer, Charles
Bernabeu, Carmelo
Nachtigal, Petr
author_sort Tripska, Katarina
collection PubMed
description Endoglin (Eng) is a co-receptor of the transforming growth factor β superfamily playing an important role in endothelial dysfunction. TRC105 (carotuximab) is a monoclonal antibody that blocks Eng and its downstream Smad signaling pathway. Here we have investigated for the first time the effects of TRC105 treatment on the development of endothelial dysfunction induced by 7-ketocholesterol (7K) or high glucose (HG), focusing on Eng expression, signaling, and function. In the hypercholesterolemia study, human aortic endothelial cells (HAoECs) were treated with TRC105 (300 μg/ml) for 1 h, followed by the addition of 7K (10 μg/ml) for another 12 h. In the hyperglycemia study, HAoECs were exposed to HG (45 mM) for 60 h, followed by the addition of TRC105 for another 12 h, and cells treated with 5mM glucose and 40 mM mannitol served as control. Protein levels, adhesion, and transmigration of monocytes were assessed by flow cytometry, mRNA expression was measured by qRT-PCR. 7K and HG treatment increased protein levels of NF-κB and Eng and adhesion and transmigration of monocytes through HAoECs monolayer. TRC105 pretreatment reduced the 7K- or HG-induced Eng protein levels and pSmad1/5 and pSmad2/3 signaling. Despite increased protein levels of P-selectin and VCAM-1, TRC105 mediated blockage of Eng prevented 7K- and HG-induced adhesion and transmigration of monocytes through endothelial monolayers. These results suggest that TRC105-mediated Eng blockage can counteract the hypercholesterolemia- and hyperglycemia-induced endothelial dysfunction in HAoECs, suggesting that Eng might be a potential therapeutic target in disorders associated with elevated cholesterol and glucose levels.
format Online
Article
Text
id pubmed-9490272
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94902722022-09-22 Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells Tripska, Katarina Igreja Sá, Ivone Cristina Vasinova, Martina Vicen, Matej Havelek, Radim Eissazadeh, Samira Svobodova, Zuzana Vitverova, Barbora Theuer, Charles Bernabeu, Carmelo Nachtigal, Petr Front Med (Lausanne) Medicine Endoglin (Eng) is a co-receptor of the transforming growth factor β superfamily playing an important role in endothelial dysfunction. TRC105 (carotuximab) is a monoclonal antibody that blocks Eng and its downstream Smad signaling pathway. Here we have investigated for the first time the effects of TRC105 treatment on the development of endothelial dysfunction induced by 7-ketocholesterol (7K) or high glucose (HG), focusing on Eng expression, signaling, and function. In the hypercholesterolemia study, human aortic endothelial cells (HAoECs) were treated with TRC105 (300 μg/ml) for 1 h, followed by the addition of 7K (10 μg/ml) for another 12 h. In the hyperglycemia study, HAoECs were exposed to HG (45 mM) for 60 h, followed by the addition of TRC105 for another 12 h, and cells treated with 5mM glucose and 40 mM mannitol served as control. Protein levels, adhesion, and transmigration of monocytes were assessed by flow cytometry, mRNA expression was measured by qRT-PCR. 7K and HG treatment increased protein levels of NF-κB and Eng and adhesion and transmigration of monocytes through HAoECs monolayer. TRC105 pretreatment reduced the 7K- or HG-induced Eng protein levels and pSmad1/5 and pSmad2/3 signaling. Despite increased protein levels of P-selectin and VCAM-1, TRC105 mediated blockage of Eng prevented 7K- and HG-induced adhesion and transmigration of monocytes through endothelial monolayers. These results suggest that TRC105-mediated Eng blockage can counteract the hypercholesterolemia- and hyperglycemia-induced endothelial dysfunction in HAoECs, suggesting that Eng might be a potential therapeutic target in disorders associated with elevated cholesterol and glucose levels. Frontiers Media S.A. 2022-09-07 /pmc/articles/PMC9490272/ /pubmed/36160139 http://dx.doi.org/10.3389/fmed.2022.845918 Text en Copyright © 2022 Tripska, Igreja Sá, Vasinova, Vicen, Havelek, Eissazadeh, Svobodova, Vitverova, Theuer, Bernabeu and Nachtigal. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Tripska, Katarina
Igreja Sá, Ivone Cristina
Vasinova, Martina
Vicen, Matej
Havelek, Radim
Eissazadeh, Samira
Svobodova, Zuzana
Vitverova, Barbora
Theuer, Charles
Bernabeu, Carmelo
Nachtigal, Petr
Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells
title Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells
title_full Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells
title_fullStr Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells
title_full_unstemmed Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells
title_short Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells
title_sort monoclonal anti-endoglin antibody trc105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490272/
https://www.ncbi.nlm.nih.gov/pubmed/36160139
http://dx.doi.org/10.3389/fmed.2022.845918
work_keys_str_mv AT tripskakatarina monoclonalantiendoglinantibodytrc105carotuximabpreventshypercholesterolemiaandhyperglycemiainducedendothelialdysfunctioninhumanaorticendothelialcells
AT igrejasaivonecristina monoclonalantiendoglinantibodytrc105carotuximabpreventshypercholesterolemiaandhyperglycemiainducedendothelialdysfunctioninhumanaorticendothelialcells
AT vasinovamartina monoclonalantiendoglinantibodytrc105carotuximabpreventshypercholesterolemiaandhyperglycemiainducedendothelialdysfunctioninhumanaorticendothelialcells
AT vicenmatej monoclonalantiendoglinantibodytrc105carotuximabpreventshypercholesterolemiaandhyperglycemiainducedendothelialdysfunctioninhumanaorticendothelialcells
AT havelekradim monoclonalantiendoglinantibodytrc105carotuximabpreventshypercholesterolemiaandhyperglycemiainducedendothelialdysfunctioninhumanaorticendothelialcells
AT eissazadehsamira monoclonalantiendoglinantibodytrc105carotuximabpreventshypercholesterolemiaandhyperglycemiainducedendothelialdysfunctioninhumanaorticendothelialcells
AT svobodovazuzana monoclonalantiendoglinantibodytrc105carotuximabpreventshypercholesterolemiaandhyperglycemiainducedendothelialdysfunctioninhumanaorticendothelialcells
AT vitverovabarbora monoclonalantiendoglinantibodytrc105carotuximabpreventshypercholesterolemiaandhyperglycemiainducedendothelialdysfunctioninhumanaorticendothelialcells
AT theuercharles monoclonalantiendoglinantibodytrc105carotuximabpreventshypercholesterolemiaandhyperglycemiainducedendothelialdysfunctioninhumanaorticendothelialcells
AT bernabeucarmelo monoclonalantiendoglinantibodytrc105carotuximabpreventshypercholesterolemiaandhyperglycemiainducedendothelialdysfunctioninhumanaorticendothelialcells
AT nachtigalpetr monoclonalantiendoglinantibodytrc105carotuximabpreventshypercholesterolemiaandhyperglycemiainducedendothelialdysfunctioninhumanaorticendothelialcells